Ticker Symbol: FBRX
Forte Biosciences Inc
$3.19 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001419041
Company Profile
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. In September 2020, Forte initiated a multi-center, placebo controlled clinical trial of FB-401 which is expected to enroll pediatric, adolescent and adult AD subjects aged 2 years of age and older.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 1124 W Carson Street
Website: www.fortebiorx.com
CEO: Martin Duvall
Tags:
- Health Technology
- Biotechnology
- Health Services
- Medical/Nursing Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.60
Change:
-$0.01
(
-2.47%)
Days Range: $0.60 - $0.62
Beta: 0.41
52wk. High: $1.29
52wk. Low: $0.52
Ytd. Change -40.55%
50 Day Moving Average: $0.71
200 Day Moving Average: $0.92
Shares Outstanding: 36281772
Valuation
Market Cap: 2.2B
PE Ratio: -0.04
EPS (TTM): -13.46
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A